OTCMKTS:RSLSD ReShape Lifesciences (RSLSD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About ReShape Lifesciences Stock (OTCMKTS:RSLSD) Get ReShape Lifesciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume6,500 shsAverage Volume1,362 shsMarket Capitalization$1.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ReShape Lifesciences Inc. is a medical device and healthcare company focused on treatments for obesity and related metabolic conditions. Its primary business centers on minimally invasive approaches to weight management, with products intended to support long-term weight loss and obesity care. The company’s principal product is the LAP-BAND Adjustable Gastric Banding System, an implantable device designed to restrict food intake by placing an adjustable band around the upper portion of the stomach. ReShape Lifesciences has also offered patient-support and digital health services, including programs intended to complement medical weight-loss treatment through education, monitoring and lifestyle guidance. The company traces its history to EnteroMedics, a developer of medical technologies for obesity, and adopted the ReShape Lifesciences name following its combination with ReShape Medical. Its business has primarily served patients and healthcare providers in the United States, with its products and services also having an international presence where regulatory approvals and commercial arrangements permit.AI Generated. May Contain Errors. Read More Receive RSLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RSLSD Stock News HeadlinesReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive License Agreement With Biorad Medisys for Obalon Gastric Balloon SystemSeptember 21, 2023 | finanznachrichten.deReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon SystemSeptember 21, 2023 | finance.yahoo.comElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.September 24 at 1:00 AM | Porter & Company (Ad)ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0June 26, 2023 | finance.yahoo.comReShape Lifesciences® to Participate in Investor and Industry Conferences in JuneJune 14, 2023 | finance.yahoo.comReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2023 Earnings Call TranscriptMay 17, 2023 | insidermonkey.comReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-MarketApril 20, 2023 | finance.yahoo.comReShape Lifesciences(R) Receives Notice of Allowance for U.S. Patent Related to its Obalon(R) Balloon SystemApril 12, 2023 | marketwatch.comSee More Headlines RSLSD Stock Analysis - Frequently Asked Questions How do I buy shares of ReShape Lifesciences? Shares of RSLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:RSLSD CIKN/A Webwww.enteromedics.com Phone949-429-6680FaxN/AEmployees50Year Founded2002Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$81.15 million Net Margins-668.58% Pretax MarginN/A Return on Equity-163.22% Return on Assets-52.10% Debt Debt-to-Equity Ratio0.05 Current Ratio1.17 Quick Ratio1.07 Sales & Book Value Annual Sales$610 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.08 Book Value$341.84 per share Price / BookN/AMiscellaneous Outstanding Shares354,000Free FloatN/AMarket Cap$1.90 million OptionableNot Optionable Beta2.03 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:RSLSD) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ReShape Lifesciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
